The GO-consortium is an initiative from the Radboud University Medical Centre in Nijmegen, the Netherlands. This is the team that is responsible for the design and execution of the project.
Marieke Coenen, PhD
My research entails pharmacogenetic studies from the identification of new pharmacogenetic variants to implementation studies. This study fits well with other research project focussing on pharmacogenetics of childhood cancer (e.g. pharmacogenetics of brain tumours) in which we aim to optimise treatment for these patients. Together with Maroeska te Loo, we are the initators of the GO-consortium.
Maroeska te Loo, MD PhD
Pediatric Hematologist and Clinical Pharmacologist
My research focuses mainly on the pharmacology of medicines in children, including pharmacogenetics. In this, I have focused on rare diseases like osteosarcoma as in this patient group there is a lot to win: patients experience a high burden due to treatment and survival rates reached a plateau the past three decades. Together with Marieke Coenen, we are the initiators of the GO-consortium.
After obtaining my MSc in Biomedical Sciences at the Radboud University in August 2017, I continued as a PhD student in the GO-consortium project. I am currently investigating the role of genetic variation in response to treatment and toxicities in osteosarcoma patients.
Johanne Groothuismink, BASc
After working on genetic variation in several multifactorial diseases since 2007. She is currently working on pharmacogenetic variation in response to treatment in osteosarcoma patients.
Mascha Schijvenaars, BASc
After working on genetics of various multifactorial diseases since 2000, Mascha is now involved in research on the role of genetic variation in response to pharmacological treatment in osteosarcoma patients.